Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Circulation Doodle
      • Doodle Gallery
      • Circulation Cover Doodle
        • → Blip the Doodle
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
    • Subscribe to AHA Journals
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
      • Recently Published Guidelines
    • Bridging Disciplines
    • Circulation at Major Meetings
    • Special Themed Issues
    • Global Impact of the 2017 ACC/AHA Hypertension Guidelines
    • Circulation Supplements
    • Cardiovascular Case Series
    • ECG Challenge
    • Hospitals of History
      • Brigham and Women's Hospital
      • Hartford Hospital
      • Hospital Santa Maria del Popolo, Naples, Italy
      • Instituto do Coração-INCOR (São Paulo, Brasil)
      • Minneapolis City Hospital
      • Parkland Hospital: Dallas, Texas
      • Pennsylvania Hospital, Philadelphia
      • Pitié-Salpêtrière Hospital
      • Royal Infirmary of Edinburgh, Scotland
      • Tufts Medical Center
      • University of Michigan
      • Uppsala University Hospital
      • Vassar Brothers Medical Center (Poughkeepsie, NY)
      • Wroclaw Medical University
      • Women's College Hospital, Toronto, Canada
      • Henry Ford Hospital, Detroit, Michigan
      • Instituto Nacional de Cardiología Ignacio Chávez – INCICh México City, México
      • Kuang-Tien General Hospital (Taichug, Taiwan)
    • On My Mind
    • Podcast Archive
    • → Subscribe to Circulation on the Run
    • →Circulation FIT Podcast 2018
    • → #FITFAVs
  • Resources
    • Instructions for Authors
      • Accepted Manuscripts
      • Revised Manuscripts
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • Journal Policies
    • Permissions and Rights Q&A
    • Submission Sites
    • Circulation CME
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Circulation Doodle
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
    • Subscribe to AHA Journals
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Bridging Disciplines
    • Circulation at Major Meetings
    • Special Themed Issues
    • Global Impact of the 2017 ACC/AHA Hypertension Guidelines
    • Circulation Supplements
    • Cardiovascular Case Series
    • ECG Challenge
    • Hospitals of History
    • On My Mind
    • Podcast Archive
    • → Subscribe to Circulation on the Run
    • →Circulation FIT Podcast 2018
    • → #FITFAVs
  • Resources
    • Instructions for Authors
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • Journal Policies
    • Permissions and Rights Q&A
    • Submission Sites
    • Circulation CME
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Brief Rapid Communication

Chlamydia pneumoniae Infection of Vascular Smooth Muscle and Endothelial Cells Activates NF-κB and Induces Tissue Factor and PAI-1 Expression

A Potential Link to Accelerated Arteriosclerosis

Ralf Dechend, M. Maass, J. Gieffers, R. Dietz, C. Scheidereit, A. Leutz, D. C. Gulba
Download PDF
https://doi.org/10.1161/01.CIR.100.13.1369
Circulation. 1999;100:1369-1373
Originally published September 28, 1999
Ralf Dechend
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Maass
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Gieffers
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Dietz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Scheidereit
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Leutz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. C. Gulba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Abstract

Background—Recent reports link C. pneumoniae infection of arteriosclerotic lesions to the precipitation of acute coronary syndromes, which also feature tissue factor and plasminogen activator inhibitor 1 (PAI-1) overexpression. We investigated whether or not C. pneumoniae can induce thrombogenicity by upregulation of procoagulant proteins.

Methods and Results—Human vascular endothelial and smooth muscle cells were infected with a strain of C. pneumoniae isolated from an arteriosclerotic coronary artery. Tissue factor, PAI-1, and interleukin-6 expression was increased in infected cells. Concomitantly, NF-κB was activated and IκBα degraded. p50/p65 heterodimers were identified as the components responsible for the NF-κB activity.

Conclusions—These data provide evidence that C. pneumoniae infection can induce procoagulant protein and proinflammatory cytokine expression. This cellular response is accompanied by activation of NF-κB. Our results demonstrate how C. pneumoniae infection may initiate acute coronary syndromes.

  • plasminogen activator inhibitor 1
  • tissue factor
  • interleukins
  • arteriosclerosis
  • C. pneumoniae

Arteriosclerosis involves genetic and environmental influences.1 In addition to gradual arteriosclerotic progression, plaque erosion and rupture may occur with mural thrombosis, sudden luminal narrowing, or abrupt vessel closure. The clinical consequence is the acute coronary syndrome (ACS).2 Recent data from epidemiological, histopathological, and intervention studies suggest a role of C. pneumoniae infection in the pathogenesis of ACS.3 4 However, the molecular mechanisms are poorly understood. Macrophages may be recruited to the plaque causing weakening of the fibrous cap and subsequent plaque rupture.5 Thrombogenicity participates in the precipitation of ACS.6 We reasoned that C. pneumoniae infection might increase the thrombogenicity of infected plaques. We examined tissue factor (TF) and plasminogen activator inhibitor 1 (PAI-1) expression in human vascular smooth muscle (VSMC) and endothelial cells (EC). Increased TF, PAI-1, and interleukin-6 (IL-6) were found after C. pneumoniae infection. Enhanced thrombogenicity was accompanied by sustained activation of the nuclear transcription factor NF-κB p50/p65 heterodimer and the simultaneous degradation of the inhibitor protein IκBα. Our findings suggest that C. pneumoniae infection induces procoagulant protein and proinflammatory cytokine expression via NF-κB activation. We suggest that this process may precipitate ACS.

Materials and Methods

C. pneumoniae infection was established in primary cultures of human VSMCs (Clonetics, San Diego, Calif) and in the immortalized human venous endothelial cell line ECV-304 (ATCC CRL 1998). Stock suspensions were prepared from the vascular C. pneumoniae strain CV-4, isolated from an arteriosclerotic coronary artery as described earlier.7 C. pneumoniae growth was monitored 72 hours after infection using a fluorescein isothiocyanate-conjugated C. pneumoniae-specific monoclonal antibody (DAKO, Copenhagen, Denmark). Cells were also continuously checked for detachment from plates and cell lysis. Cells were harvested at different time points for electrophoretic mobility shift assay (EMSA) and lysed in whole cell lysate buffer. Labeling and binding reaction were performed as described.8 The DNA probe contained the κB site from the MHC-enhancer (H2K) or the H2B octamer binding site. EMSAs were repeated 3 times and representative gels are shown. Polyclonal antisera to NF-κB proteins p50, p65, c-Rel, and RelB were purchased from Santa Cruz Biotechnology Inc, Calif. For immunoblotting, whole cell lysates were prepared, quantified by standard Bradford assay, and immunoblotting was performed as described.9 TF and PAI-1 were obtained from Loxo (GmbH, Dossenheim, Germany); IL-6 and tubulin from Genzyme (Framinghman, Mass). Protein concentrations of the cellular supernatants were quantified for ELISA using the Bradford method. IL-6 (Quantikine Immunoassay, R&D Systems, Minneapolis Minn) and PAI-1 (American Diagnostics, Greenwich, Conn) were determined by ELISA. TF activity was determined in cell extracts with a clotting based assay (ACTICLOT, Diagnostics International, Karlsdorf, Germany).

Results

Figure 1A⇓ shows infection of human ECs and VSMCs. Intracellular inclusion bodies are visible, they contain actively replicating C. pneumoniae of the CV-4 strain isolated from infected coronary plaques.10

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

A, C. pneumoniae infection of EC and HASMC. Immunofluorescence staining reveals large intracellular inclusion bodies containing actively replicating C. pneumoniae, 72 hours after infection. B, Effects of C. pneumoniae infection on cellular expression of TF, PAI-1, and IL-6. Immunoblot analysis of cellular extracts prepared from ECs (left) and HASMCs (right) at different time points after C pneumoniae or mock infection. Tubulin expression was determined as a control. Densitometry quantification values (NIH Image Program Version 1.61) are given in arbitrary units (AU) below each time point. C, Open and solid bars represent TF activity in EC extracts of mock-infected and infected cells, respectively (left). ▪ and • represent supernatant PAI-1 and IL-6 levels in infected and mock-infected endothelial cells, respectively, determined by ELISA (center and right). Data and standard deviation represent mean of triplicates.

Figure 1B⇑ shows TF, PAI-1, tubulin, and IL-6 expression in cellular EC lysates. TF expression was increased 4 hours after infection, reached maximum by 48 hours, and was sustained for the entire 72-hour study period. Increased PAI-1 expression plateaued at 4 hours and was sustained throughout the 72 hours (Figure 1B⇑). Tubulin expression was not influenced by infection, whereas IL-6 expression was increased by 4 hours. Similar effects were found in VSMCs; however, C. pneumoniae-induced TF and PAI-1 expression was lower in VSMCs than in ECs, as demonstrated by quantification (Figure 1B⇑). In the supernatant of infected ECs, PAI-1 and IL-6 levels were induced nearly 4- and 6-fold, respectively, and remained elevated throughout the 72 hours of study (Figure 1C⇑, center and right). In addition, as shown by a functional assay, TF coagulant activity of the cellular extracts increased to a similar extent as TF protein expression (Figure 1C⇑, left).

NF-κB is an important transcriptional regulator for TF and IL-6 expression.11 12 Moreover, additional data suggest that PAI-1 expression is also under the control of NF-κB.13 14 Furthermore, NF-κB is activated by microbial infection.15 EMSA results are shown in Figure 2A⇓. NF-κB activity was increased at 4 hours after C. pneumoniae infection and persisted over 72 hours in ECs and VSMCs. However, the DNA-protein complex formation shows somewhat different time-steps in the two cell types. The induced DNA complexes observed at 4 hours postinfection in HASMCs remain almost constant during the entire observation period. In ECs, however, transient DNA-protein complex was detected 24 hours postinfection in ECs. Only weak NF-κB DNA binding activity was seen in both mock-infected cell types. Competitive inhibition by unlabeled H2K oligonucleotides, but not by an AP-1 DNA binding site (Figure 2B⇓), suggests specificity of the interaction. Moreover, activation of NF-κB was specific because the DNA binding activity of endogenous octamer-binding transcription factor 1 was not affected (Figure 2A⇓). We performed antibody supershift experiments to determine which components of the NF-κB family were activated by C. pneumoniae. Addition of p65 and p50, but not p52, c-Rel, or RelB antibodies, resulted in supershifts (Figure 2B⇓). Immunoblot analysis demonstrated that C. pneumoniae infection was associated with a loss of IκBα protein, starting at 4 hours and reaching a maximum at 48 hours (Figure 2C⇓). IκBα levels were restored by 72 hours. Taken together, these data show that C. pneumoniae infection results in NF-κB p50/p65 heterodimer activation and expression of procoagulant and proinflammatory proteins.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

A, Top, kinetics of NF-κB activation in cellular extracts of ECs (left) and HASMCs (right) analyzed by EMSA. Arrows 1, 2, and 3 represent p50/p65, p50/p50, and unspecific complexes, respectively. Bottom, OCT-1 DNA binding activity on the H2B site, used as a control; oct-1 indicates octamer-binding transcription factor 1. B, Subunit composition of C. pneumoniae-induced NF-κB DNA binding activity. The antibody-supershifted complexes (AS) are indicated. Competition with unlabeled NF-κB and AP-1 oligonucleotide is demonstrated. C, IκBα protein level after infection with C. pneumoniae or mock infection analyzed by immunoblotting.

Discussion

The important findings in this study were that C. pneumoniae infection of human EC and VSMC resulted in TF, PAI-1, and IL-6 overexpression. Moreover, we demonstrated that C. pneumoniae infection resulted in NF-κB activation. NF-κB remained upregulated for at least 72 hours and was accompanied by IκBα degradation. Although C. pneumoniae belong to the eubacteria, they have no close relatives among the known bacterial genera and a direct activation of NF-κB by C. pneumoniae infection has not been shown thus far.

Plaque rupture and increased thrombogenicity are prime mechanisms of ACS.2 6 Because chronic C. pneumoniae infection is linked to the precipitation of ACS,3 4 we examined whether infections with a C. pneumoniae strain isolated from such a coronary plaque would increase the expression of prothrombotic proteins in vascular cells. We found induced and sustained expression of functionally active TF and PAI-1. Our results agree with reports from Rickettsia rickettsii-infected ECs overexpressing TF, PAI-1, IL-1, IL-6, and IL-8.16 Furthermore, infection of ECs with different Chlamydia strains also induce TF overexpression.17 Thus, the alteration of the epi/pericellular hemostatic protein expression observed here is not necessarily specific for the vascular C. pneumoniae strain that we used.

In addition to an increased procoagulation protein expression, functional cytokines are expressed in human arteriosclerotic lesions.1 IL-6 is an important mediator of inflammation in cardiovascular tissue.18 IL-6 is highly expressed in arteriosclerotic lesions,19 implicated in plaque instability,20 and in the pathogenesis of acute myocardial infarction.18 C. pneumoniae infection induced sustained cellular overexpression and secretion of IL-6. Recruitment of mesenchymal and immunocompetent cells, proliferation, and migration of VSMCs are the consequences of cytokine overexpression in the arteriosclerotic plaque.21 This state of affairs further perturbs the anticoagulant activities. The functional cooperation between products of the coagulation cascade and cytokine-mediated inflammatory response has been shown to transform a stable plaque into an unstable plaque.21 In this context, colocalization of human heat shock protein 60 (hsp) with chlamydial hsp 60 in macrophages was demonstrated. Both hsp forms induced proinflammatory cytokines such as TNF-α and metalloproteinases.5

TF and IL-6 are transcriptionally regulated by NF-κB.11 12 Furthermore, data have been presented that PAI-1 protein expression is also under the control of NF-κB.13 However, these data are less compelling. In addition, inhibition of TNF-α–induced PAI-1, TF, and IL-6 activation was achieved when NF-κB activity was inhibited with the antioxidant pyrrolidine dithiocarbamate.14 Therefore, current knowledge suggests a common link between C. pneumoniae infection, TF, PAI-1, IL-6 expression, and NF-κB. We therefore investigated whether NF-κB activity is induced in response to C. pneumoniae infection. We showed that after infection, p50/p65 heterodimer activity was upregulated in association with degradation of IκBα. Our findings therefore suggest that the C. pneumoniae-induced overexpression of TF, PAI-1, and IL-6 is transcriptionally regulated by NF-κB.

Recent data underscored the role of NF-κB in the pathogenesis of arteriosclerosis.15 22 ECs, VSMCs, and macrophages harvested and grown from arteriosclerotic lesions express activated NF-κB. Our findings are consistent with data showing that R. rickettsii-induced TF overexpression was controlled by NF-κB.16 R. rickettsii are not phylogenetically related; however, they share characteristics with C. pneumoniae, including obligate intracellular lifestyle, Gram-negative cell wall composition, and the ability to infect ECs. Interestingly, R. rickettsii has been shown to mediate NF-κB induced transcriptional activation, resulting in the inhibition of EC apoptosis.23 A similar mechanism in C. pneumoniae infection might provide an explanation for chlamydial persistence in the endothelium and a continuous inflammatory stimulus within the vascular wall. We are the first to show that NF-κB is activated in response to C. pneumoniae infection.

Our data suggest that chronic C. pneumoniae infection in the cellular components of plaques can result in increased cellular and epi/pericellular procoagulant protein expression and increased chemoattractant activity through activated NF-κB. Both effects could enhance the vulnerability of arteriosclerotic plaques. Our results add to the understanding of the role of C. pneumoniae bacteria in the mechanism of accelerated arteriosclerotic disease.

Acknowledgments

R. Dechend and M.M. were supported by the Deutsche Forschungsgemeinschaft (DE-631/1-1) and (Ma 2070/2-1).

  • Received June 25, 1999.
  • Revision received August 10, 1999.
  • Accepted August 10, 1999.
  • Copyright © 1999 by American Heart Association

References

  1. ↵
    Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809.
    OpenUrlCrossRefPubMed
  2. ↵
    Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 1997; 336:1276–1282.
  3. ↵
    Mlot C. Chlamydia linked to atherosclerosis. Science. 1996;272:1422.
    OpenUrlCrossRefPubMed
  4. ↵
    Capron L. Chlamydia in coronary plaques—hidden culprit or harmless hobo? Nat Med. 1996; 2:856–857.
  5. ↵
    Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation. 1998;98:300–307.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Fuster V, Fallon JT, Nemerson Y. Coronary thrombosis. Lancet. 1996;348:7–10.
    OpenUrlCrossRefPubMed
  7. ↵
    Maass M, Bartels C, Engel PM, Mamat U, Sievers HH. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol. 1998;31:827–831.
    OpenUrlCrossRefPubMed
  8. ↵
    Dechend R, Hirano F, Lehmann K, Heissmeyer V, Ansieau S, Wulczyn FG, Scheidereit C, Leutz A. The Bcl-3 oncoprotein acts as a bridging factor between NF-kB/Rel and nuclear co-regulators. Oncogene. 1999;18:3316–3323.
    OpenUrlCrossRefPubMed
  9. ↵
    Kowenz Leutz E, Twamley G, Ansieau S, Leutz A. Novel mechanism of C/EBP beta (NF-M) transcriptional control: activation through derepression. Genes Dev. 1994;8:2781–2791.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Bartels C, Maass M, Bein G, Malisius R, Brill N, Bechtel JFM, Sayk F, Feller AC, Sievers HH. Detection of Chlamydia pneumoniae but not CMV in occluded saphenous vein coronary-artery bypass grafts. Circulation. 1999;99:879–882.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Moll T, Czyz M, Holzmuller H, Hofer Warbinek R, Wagner E, Winkler H, Bach FH, Hofer E. Regulation of the tissue factor promoter in endothelial cells. Binding of NF kappa B-, AP-1-, and Sp1-like transcription factors. J Biol Chem. 1995;270:3849–3857.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Muraoka K, Shimizu K, Sun X, Zhang YK, Tani T, Hashimoto T, Yagi M, Miyazaki I, Yamamoto K. Hypoxia, but not reoxygenation, induces interleukin 6 gene expression through NF-kappa B activation. Transplantation. 1997;63:466–470.
    OpenUrlCrossRefPubMed
  13. ↵
    Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the PAI-1 gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 1993;268:10739–10745.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Ferran C, Millan MT, Csizmadia V, Cooper JT, Brostjan C, Bach FH, Winkler H. Inhibition of NF-kappa B by pyrrolidine dithiocarbamate blocks endothelial cell activation. Biochem Biophys Res Commun. 1995;214:212–223.
    OpenUrlCrossRefPubMed
  15. ↵
    Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066–1071.
    OpenUrlCrossRefPubMed
  16. ↵
    Shi RJ, Simpson Haidaris PJ, Lerner NB, Marder VJ, Silverman DJ, Sporn LA. Transcriptional regulation of endothelial cell tissue factor expression during Rickettsia rickettsii infection: involvement of the transcription factor NF-kappaB. Infect Immun. 1998;66:1070–1075.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Fryer RH, Schwobe EP, Woods ML, Rodgers GM. Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J Investig Med. 1997;45:168–174.
    OpenUrlPubMed
  18. ↵
    Kukielka GL, Youker KA, Hawkins HK, Perrard JL, Michael LH, Ballantyne CM, Smith CW, Entman ML. Regulation of ICAM-1 and IL-6 in myocardial ischemia: effect of reperfusion. Ann N Y Acad Sci. 1994;723:258–270.
    OpenUrlPubMed
  19. ↵
    Seino Y, Ikeda U, Ikeda M, Yamamoto K, Misawa Y, Hasegawa T, Kano S, Shimada K. Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine. 1994;6:87–91.
    OpenUrlCrossRefPubMed
  20. ↵
    Yazdani S, Simon AD, Vidhun R, Gulotta C, Schwartz A, Rabbani LE. Inflammatory profile in unstable angina versus stable angina in patients undergoing percutaneous interventions. Am Heart J. 1998;136:357–361.
    OpenUrlCrossRefPubMed
  21. ↵
    Hansson GK. Immunological control mechanisms in plaque formation. Basic Res Cardiol. 1994;89(suppl 1):41–46.
  22. ↵
    Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D. Activated transcription factor NF-κB is present in the atherosclerotic lesion. J Clin Invest. 1996;97:1715–1722.
    OpenUrlCrossRefPubMed
  23. ↵
    Clifton DR, Goss RA, Sahni SK, van Antwerp D, Baggs RB, Marder VJ, Silverman DJ, Sporn LA. NF-kappa B-dependent inhibition of apoptosis is essential for host cell survival during Rickettsia rickettsii infection. Proc Natl Acad Sci U S A. 1998;95:4646–4651.
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Circulation
September 28, 1999, Volume 100, Issue 13
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Chlamydia pneumoniae Infection of Vascular Smooth Muscle and Endothelial Cells Activates NF-κB and Induces Tissue Factor and PAI-1 Expression
    Ralf Dechend, M. Maass, J. Gieffers, R. Dietz, C. Scheidereit, A. Leutz and D. C. Gulba
    Circulation. 1999;100:1369-1373, originally published September 28, 1999
    https://doi.org/10.1161/01.CIR.100.13.1369

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Chlamydia pneumoniae Infection of Vascular Smooth Muscle and Endothelial Cells Activates NF-κB and Induces Tissue Factor and PAI-1 Expression
    (Your Name) has sent you a message from Circulation
    (Your Name) thought you would like to see the Circulation web site.
  • Share on Social Media
    Chlamydia pneumoniae Infection of Vascular Smooth Muscle and Endothelial Cells Activates NF-κB and Induces Tissue Factor and PAI-1 Expression
    Ralf Dechend, M. Maass, J. Gieffers, R. Dietz, C. Scheidereit, A. Leutz and D. C. Gulba
    Circulation. 1999;100:1369-1373, originally published September 28, 1999
    https://doi.org/10.1161/01.CIR.100.13.1369
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Heart Failure and Cardiac Disease
    • Myocardial Infarction
  • Epidemiology, Lifestyle, and Prevention
    • Exercise
    • Epidemiology
  • Cardiology
    • Etiology
      • Acute myocardial infarction
  • Stroke
    • Ischemic Stroke

Circulation

  • About Circulation
  • Instructions for Authors
  • Circulation CME
  • Statements and Guidelines
  • Meeting Abstracts
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
200 Fifth Avenue, Suite 1020
Waltham, MA 02451
email: circ@circulationjournal.org
 

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured